ID   KON
AC   CVCL_3001
DR   CLO; CLO_0009946
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 913
DR   BioSample; SAMN03471653
DR   cancercelllines; CVCL_3001
DR   Cell_Model_Passport; SIDM00604
DR   CGH-DB; 369-2
DR   Cosmic; 1995473
DR   Cosmic-CLP; 1298215
DR   DepMap; ACH-001542
DR   EGA; EGAS00001000978
DR   GDSC; 1298215
DR   GEO; GSM827191
DR   GEO; GSM1669999
DR   JCRB; JCRB0194
DR   LINCS_LDP; LCL-1207
DR   PharmacoDB; KON_778_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3001
DR   Wikidata; Q54900289
RX   DOI=10.5794/jjoms.41.19;
RX   PubMed=17599052;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 32.5 hours (Note=At 28th passage) (DOI=10.5794/jjoms.41.19); 43 hours (Note=Lot 01262007) (JCRB=JCRB0194).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; CRISPR screening.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0.36%; Native American=0.46%; East Asian, North=79.36%; East Asian, South=18.6%; South Asian=0.7%; European, North=0.27%; European, South=0.25% (PubMed=30894373).
CC   Misspelling: KOS; CGH-DB=369-2.
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): Cosmic-CLP=1298215; DepMap=ACH-001542; JCRB=JCRB0194
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 9,11
ST   D18S51: 14,15
ST   D21S11: 29,30
ST   D3S1358: 16
ST   D5S818: 11,13
ST   D7S820: 8,11
ST   D8S1179: 10,14
ST   FGA: 22,24
ST   Penta D: 9
ST   Penta E: 12,16
ST   TH01: 7,9
ST   TPOX: 9,11
ST   vWA: 16,17 (JCRB=JCRB0194)
ST   vWA: 17 (Cosmic-CLP=1298215; DepMap=ACH-001542)
DI   NCIt; C4041; Floor of mouth squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   76Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 35
//
RX   DOI=10.5794/jjoms.41.19;
RA   Ohara M., Yasui A., Ishikawa T.;
RT   "Establishment and characterization of a human oral squamous cell
RT   carcinoma cell line (KON).";
RL   Nihon Koku Geka Gakkai Zasshi 41:19-25(1995).
//
RX   PubMed=17599052; DOI=10.1038/sj.onc.1210589;
RA   Suzuki E., Imoto I., Pimkhaokham A., Nakagawa T., Kamata N.,
RA   Kozaki K.-i., Amagasa T., Inazawa J.;
RT   "PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in
RT   oral squamous-cell carcinomas by aberrant promoter hypermethylation.";
RL   Oncogene 26:7921-7932(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//